<DOC>
	<DOC>NCT00779779</DOC>
	<brief_summary>This Post Marketing Surveillance (PMS) will collect reactogenicity and safety data on the use of human rotavirus vaccine in healthy infants aged from 6 weeks (first dose) to not more than 24 weeks (second dose).</brief_summary>
	<brief_title>Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarixâ„¢ (Human Rotavirus Vaccine) in Infants</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol . A male or female at least 6 weeks of age at the time of the first vaccination. Written informed consent obtained from the parent or guardian of the subject. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Acute disease at the time of enrolment. Any history of uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception. Any contraindication as stated in the updated and approved Prescribing Information</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>19 Weeks</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Gastroenteritis</keyword>
</DOC>